Clinical Trial Update: QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

This document reports that the Phase 2 trial of QL1706 for neoadjuvant treatment of HR+/HER2- breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Breast Cancer, HR+/HER2- Breast Cancer | Phase 2 | Status: RECRUITING